Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

BioVaxys Technology Corp. C.BIOV

Alternate Symbol(s):  BVAXF

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical-stage pipeline includes maveropepimut-S, which is in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer. The Company is also leveraging its expertise in tumor immunology by creating a unique library of T-lymphocytes and other datasets post-vaccination with its personalized immunotherapeutic vaccines to identify new targetable tumor antigens.


CSE:BIOV - Post by User

BioVaxys Technology Corp. > BIOV 3.1 MILLION BROKER ACCUMULATION ON NO NEWS!!
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(400)
•••
Comment by moneywagonon Oct 26, 2022 3:21pm
36 Views
Post# 35050995

RE:BIOV 3.1 MILLION BROKER ACCUMULATION ON NO NEWS!!

RE:BIOV 3.1 MILLION BROKER ACCUMULATION ON NO NEWS!!CHART
C:BIOV - BioVaxys Technology Corp. - https://biovaxys.com
Sym-X Bid - Ask Last Chg %Ch Vol $Vol #Tr Open-Hi-Lo Year Hi-Lo Last Tr News Delay
BIOV - C   2.5 0.225 · 0.235 5.0 0.235 +0.01 4.4 3,110.8 673 662 0.23  0.25  0.195 0.395  0.085 14:57:24 Oct 14 15 min RT 2¢
CSE - C 2.5 0.225 · 0.235 5.0 0.23 +0.005 2.2 1,000.7 213 279 0.23  0.25  0.195 0.395  0.085 14:55:19   15 min
NEO ATS - U   0.235 +0.01 4.4 1,902.0 415 319 0.22  0.25  0.195   14:57:24   15 min
Omega - O   0.225     189.0 41 50 0.22  0.245  0.20   14:54:44   15 min
CX2 - H   0.235 +0.01 4.4 18.5 4 9 0.21  0.235  0.20   14:05:57   15 min
CXD - D   0.225     0.2   2        Jul 04   15 min
TriAct - M   0.225     0.4   3            15 min

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities